Proprietary Blood-Based TestsFibrosis Assessment
Laboratory-Based Biomarkers • Proprietary Blood-Based Tests

Enhanced Liver Fibrosis (ELF™) Test

Direct extracellular matrix blood test measuring hyaluronic acid (HA), PIIINP, and TIMP-1 to stage liver fibrosis and assess progression risk.

What This Means for Patients

Unlike indirect scores that infer scarring from routine enzymes, the ELF test measures three molecules directly involved in building and remodeling scar tissue (collagen) inside the liver: HA, PIIINP, and TIMP-1. Look at the specificity column in the table below: at 9.8 or above, ELF has 90% specificity for advanced fibrosis (F3+), and at 11.3 or above, it has 97% specificity for cirrhosis (F4).

What Is the ELF™ Test?

  • The ELF™ test is a noninvasive blood test that measures 3 blood-based biomarkers related to liver fibrosis and changes in the ECM of the liver1

Use in MASLD/MASH Care

  • Following a positive first-line test (eg, FIB-4) result in primary care, the ELF™ test is commonly recommended as a second-line assessment as an alternative to imaging-based methods, such as elastography, particularly when imaging is unavailable or not indicated8,9

How Is It Measured?

  • 3 markers are evaluated in the ELF™ test2:
    • HA: An ECM component produced in most tissues; in MASLD, serum HA can differentiate between patients with and without cirrhosis3
    • PIIINP: A fibrosis and inflammation marker produced by HSCs during collagen synthesis4
    • TIMP-1: After liver injury stops, TIMP-1, along with TGF-β1, regulates the breakdown of excess collagen5
  • The ELF™ score is calculated on Siemens ADVIA Centaur systems6

Strengths

  • Provides a single, readily calculated score that stratifies fibrosis and progression risk1,2,4,8
  • Recommended by multiple guidelines for assessing fibrosis stage and risk of progression to cirrhosis and liver-related outcomes1,8,10,11
  • ELF™ received FDA authorization to assess the likelihood of progression to cirrhosis and liver-related clinical events in patients with advanced fibrosis (F3/F4) due to MASH6

Limitations

  • ELF™ scores can be affected by age, sex, and other factors (eg, fluorescein and hemolyzed samples)6,12
  • While reflective of liver disease, biomarkers like HA may also respond to extrahepatic conditions (eg, renal dysfunction), potentially confounding interpretation13
  • Ability of the ELF™ score to monitor changes in fibrosis and MASH resolution is not well defined14

Published Cutoff Values for Fibrosis Staging Using ELF™7

Fibrosis Stage Cutoff Sensitivity,a % Specificity,b %
F0/1 <7.7 80 42
≥F2 ≥7.7 85 38
≥F3 ≥9.8 65 90
F4 ≥11.3 38 97